ComplyRx
Built by ComplyRx

Compare clinical trial pipelines, export for presentations

mazdutide (16) vs semaglutide (16)15 active2013–2031
mazdutidesemaglutide
Key
Actual date
Anticipated
Forecast to primary completion
RecruitingActive, not recruitingNot yet recruitingCompletedUnknown status
'13
'15
'17
'19
'21
'23
'25
'27
'29
'31
mazdutide
A Study of IBI362 Evaluating Weight Loss in Obese and Overweight Chinese SubjectsP2
A Study of IBI362 in Chinese Patients With Type 2 DiabetesP2
A Study of IBI362 in Participants With Obesity or OverweightP3
A Study of IBI362 in Participants With Type 2 DiabetesP3
A Study of IBI362 in Poorly Controlled Type 2 Diabetes Patients Only Through Diet and ExerciseP3
A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or OverweightP2
A Study of LY3305677 Compared With Placebo in Adult Participants With Obesity or OverweightP2
A Study of IBI362 9 mg in Chinese Adults With ObesityP3
A Study Comparing IBI362 vs Semaglutide in Chinese Adults With Early Type 2 Diabetes and ObesityP3
A Study to Evaluate Mazdutide Compared With Placebo in Participants With Alcohol Use DisorderP2
A Study Comparing IBI362 vs Semaglutide in Chinese Overweight or Obese Adults With Metabolic Dysfunction-associated Fatty Liver Disease （MAFLD）P3
A Study of IBI362 in Chinese Subjects With Obstructive Sleep Apnea and BMI≥28 kg/m2P3
GLP-1/GCG Dual Agonist in Type 2 Diabetes With Early Dementia (LIGHT-COG Study)P3
A Study of IBI362 in Chinese Adolescents With Obesity or OverweightP3
A Study of HDM1005 in Participants With T2DM Not Controlled With Metformin Alone or in Combination With a Sodium-Glucose Cotransporter 2 (SGLT2) InhibitorP3
Efficacy and Safety of IBI362 in Hypertensive Patients With Overweight/ObesityP3
semaglutide
SUSTAIN™ 6P3
A Study Comparing the Dulaglutide Pen and the Semaglutide PenP4
STEP 6P3
FLOWP3
REMODELP3
OASIS 4P3
The Impact of Semaglutide Compared to Energy Restriction on Type 2 DiabetesP4
SAMARAP2
ACHIEVE-3P3
A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 InhibitorP3
REIMAGINE 3P3
Effects of NNC0194-0499, Cagrilintide, and Semaglutide Alone or in Combinations on Liver Damage and Alcohol Use in People With Alcohol-related Liver DiseaseP2
Steno1P3
Real-World Evaluation of Omarigliptin for Type 2 Diabetes Meliitus in BangladeshP4
A Study of BGM0504 in Participants with Type 2 DiabetesP3
MIST (Metabolic Intervention With Semaglutide and THR-β Therapy) TrialP2

Upcoming readouts

9 ahead · 2 drugs

Select a trial to load its full ClinicalTrials.gov record.

Trial Pipeline · How it works

Search, compare, export.

Three steps from drug name to a presentation-ready pipeline view, with live trial data, side by side.

  1. 01 · SEARCH

    Search drugs

    Type a drug name and see the phase 2-4 trials from ClinicalTrials.gov.

  2. 02 · COMPARE

    Compare timelines

    See start dates, primary completions, and status on one timeline, up to five drugs at once.

  3. 03 · EXPORT

    Export for your deck

    Download a branded PNG or PDF. Share the URL. Every comparison state is linkable.

FAQ

Where does the data come from?
All trial data is sourced from ClinicalTrials.gov (CTGov). Results are cached for up to 6 hours so repeat loads stay fast.
Is this free?
Yes. Compare up to five drugs and export PNG or PDF at no cost. Export requires a one-time email to join the ComplyRx waitlist.
What is ComplyRx?
ComplyRx is an all-in-one marketing/competitive intelligence platform for organisations and individuals that work in healthcare, life sciences, and the pharmaceutical industry.
Join the waitlist

Be the first to access ComplyRx

We'll let you know as soon as your spot opens to use ComplyRx.

By joining, you agree to our Privacy Policy.